Concepedia

Akshay Vaishnaw

AV

49

Publications

13.2K

Citations

39

H-Index

1996

Active since

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

University College London

The Royal Free Hospital

Covance (United Kingdom)

University of Tennessee Health Science Center

Akshay Vaishnaw is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacology, and molecular biology.

Top concepts

Publications per year

1996–2024

49

Publications

49

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

Teresa Coelho, David Adams, Ana Silva et al. · New England Journal of Medicine · 2013 · 947 citations · Full text

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine · 2016 · 738 citations · Full text

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 691 citations

A short course of BG9588 (anti–CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

Dimitrios T. Boumpas, Richard Furie, Susan Manzi et al. · Arthritis & Rheumatism · 2003 · 609 citations

Rows per page

1–5 of 49